Literature DB >> 22459491

Mass spectrometric detection of antigen-specific immunoglobulin peptides in paraneoplastic patient sera.

Peter Maat1, Martijn VanDuijn, Eric Brouwer, Lennard Dekker, Lona Zeneyedpour, Theo Luider, Peter Sillevis Smitt.   

Abstract

Paraneoplastic neurological syndromes (PNS) are severe immune mediated effects of cancer. The presence of IgG autoantibodies against onconeural antigens in serum is a hallmark of the disease. Multiple paraneoplastic antibodies have been described, including antibodies against HuD, Yo, amphiphysin and CV2. In this study, we test the hypothesis that primary amino-acid structures of the antigen binding part of antibodies from various individuals share common sequences that are specific for each auto-antigen. We selected 60 patients with PNS, associated with antibodies against HuD, Yo, Amp or CV2. Affinity purified IgG was separated using SDS-PAGE and IgG heavy chains were excised, trypsinized and subjected to tandem mass spectrometry. We selected masses that uniquely identified a PNS autoantibody group, and used MS/MS fragmentation spectra to obtain information on peptide sequences. Out of 19,173 unique masses, 28 immunoglobulin-derived peptides were found exclusively in samples from a single autoantibody defined PNS group. Our results confirm that specific peptide structures exist in the antigen binding site of IgG that are shared between individuals harboring autoantibodies against the same onconeural antigen. Thus, the immune response in these patients followed converging paths during the rearrangement, selection and maturation of immunoglobulin sequences. The identified peptides can be applied in the diagnosis of PNS, but these data also indicate that a similar approach in a variety of other diseases involving an immune response would have an appealing outlook.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459491     DOI: 10.1016/j.jaut.2012.02.002

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  5 in total

1.  Cerebrospinal-fluid-derived immunoglobulin G of different multiple sclerosis patients shares mutated sequences in complementarity determining regions.

Authors:  Vaibhav Singh; Marcel P Stoop; Christoph Stingl; Ronald L Luitwieler; Lennard J Dekker; Martijn M van Duijn; Karim L Kreft; Theo M Luider; Rogier Q Hintzen
Journal:  Mol Cell Proteomics       Date:  2013-08-22       Impact factor: 5.911

2.  Peptides from the variable region of specific antibodies are shared among lung cancer patients.

Authors:  Dominique de Costa; Ingrid Broodman; Wim Calame; Christoph Stingl; Lennard J M Dekker; René M Vernhout; Harry J de Koning; Henk C Hoogsteden; Peter A E Sillevis Smitt; Rob J van Klaveren; Theo M Luider; Martijn M Vanduijn
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

3.  IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a fab-Peptide sequence.

Authors:  Susanna L Lundström; Cátia Fernandes-Cerqueira; A Jimmy Ytterberg; Elena Ossipova; Aase H Hensvold; Per-Johan Jakobsson; Vivianne Malmström; Anca I Catrina; Lars Klareskog; Karin Lundberg; Roman A Zubarev
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

4.  SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics.

Authors:  Susanna L Lundström; Bo Zhang; Dorothea Rutishauser; Dag Aarsland; Roman A Zubarev
Journal:  Sci Rep       Date:  2017-02-07       Impact factor: 4.379

5.  Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Authors:  An-Sofie Schelpe; Elien Roose; Bérangère S Joly; Inge Pareyn; Ilaria Mancini; Marina Biganzoli; Hans Deckmyn; Jan Voorberg; Rob Fijnheer; Flora Peyvandi; Simon F De Meyer; Paul Coppo; Agnès Veyradier; Karen Vanhoorelbeke
Journal:  Haematologica       Date:  2018-12-06       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.